{
    "clinical_study": {
        "@rank": "61929", 
        "arm_group": {
            "arm_group_label": "ASP7487,  Velcade,  Dexamethasone", 
            "arm_group_type": "Experimental", 
            "description": "ASP7487 administered orally 75, 100 and 150 mg) BID continuously for each cycle. Bortezomib administered at 1.3 mg/m2 twice weekly for the first 8 21 day cycles and once weekly beyond cycle 9 for 35 day cycles. Dexamethasone is administered on bortezomib administration days at 20 mg"
        }, 
        "brief_summary": {
            "textblock": "This is a multi-center, open-label, non-randomized study.  Patients will receive ASP7487\n      (OSI-906) in combination with bortezomib and dexamethasone. Phase 1 involves dose escalation\n      of the combination, whereas Phase 2 involves the expansion of ASP7487 (OSI-906) combined\n      with bortezomib and dexamethasone at the MTD to establish the ORR.  This trial will accrue\n      patients with relapsed or relapsed/refractory MM - a disease state for which bortezomib is\n      approved to treat by the FDA and Health Canada. The combination of ASP7487 (OSI-906) with\n      bortezomib is supported by pre-clinical work in MM in which the combination with an IGF1-R\n      inhibitor enhances anti-tumor activity of bortezomib."
        }, 
        "brief_title": "A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The Phase 1 portion of the study will determine the MTD and DLTs of bortezomib administered\n      on days 1, 4, 8 and 11 of a 21-day cycle combined with ASP7487 (OSI-906) dosed twice daily\n      orally continuously. The combination of ASP7487 (OSI-906) with bortezomib has not previously\n      been tested. The active agent bortezomib will be used during Cycle 1 - 8 at the recommended\n      treatment dose of 1.3 mg/m2 days 1, 4, 8 and 11 and Cycles 9+ on days 1, 8, 15 and 22 of a\n      5-week cycle and ASP7487 (OSI-906) will be dose escalated form 75 mg to 150mg utilizing 3+3\n      design"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males or females, age 18 years or older.\n\n          2. A diagnosis of MM and documentation of relapsed or relapse/refractory status\n             following at least 1 prior therapy and a maximum of 4 prior regimens.\n\n          3. Patients with measurable disease defined as at least one of the following these\n             baseline laboratory studies for determining eligibility must be obtained within 21\n             days prior to enrollment):\n\n               1. Serum M-protein \u2265 0.5 g/dl (\u2265 5 g/l)\n\n               2. Urine M-protein \u2265 200 mg/24 h\n\n               3. Serum free light chains (FLC) assay: Involved FLC level \u2265 10 mg/dl  (\u2265100 mg/l)\n                  and an abnormal serum free light chain ratio (< 0.26 or > 1.65)\n\n               4. Biopsy proven plasmacytoma (should be measured within 28 days of first study\n                  drug administration). Prior biopsy is acceptable.\n\n               5. If the serum protein electrophoresis is unreliable for routine M-protein\n                  measurement, quantitative immunoglobulin levels on nephelometry or turbidimetry\n                  will be followed.\n\n          4. Patient has an Eastern Cooperative Oncology Group (ECOG) \u2264 2 OR Karnofsky\n\n               -  60% performance status (PS) (Appendix 13-2).\n\n          5. Predose mean QTc \u2264 450 msec or mean QTc Fridericia's Correction (QTcF)on Day 1(cycle\n             1 or cycle 0 if applicable) must be \u2264 450 msec.\n\n          6. Females of childbearing potential (FCBP):  a female of childbearing potential is a\n             sexually mature woman who: 1) has not undergone a hysterectomy or bilateral\n             oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive\n             months).  Pregnancy status in women of childbearing potential must be confirmed by\n             serum \u03b2-hCG at screening. Pregnancy testing is not required for post-menopausal or\n             surgically sterilized women. FCBP must use acceptable forms of birth control or agree\n             to abstain from heterosexual intercourse while participating in the study and for 90\n             days following the last dose of study drug. Men must agree to use a latex condom\n             during sexual contact with a FCBP even if they have had a successful vasectomy while\n             participating in the study and for 90 days following the last dose of study drug.\n\n          7. Voluntary, written informed consent before performance of any study-related procedure\n             not part of routine medical care with the understanding that consent may be withdrawn\n             by the patient at any time without prejudice to future medical care.\n\n          8. Ability to understand the purpose and risks of the study and provide signed and dated\n             informed consent and authorization to use protected health information (in accordance\n             with national and local patient privacy regulations).\n\n          9. Must be able to take and retain oral medications.\n\n         10. Inclusion Clinical Laboratories Criteria The following laboratory results must be met\n             within 7 (+3 days if necessary for holiday/scheduling conflicts) days of first study\n             drug administration:\n\n               1. Absolute neutrophil count (ANC) \u2265 1,000 cells/dL (1.0 x 10^9/L) (Growth factors\n                  cannot be used within 14 days of first study drug administration);\n\n               2. Platelet count \u2265 50,000 cells/dL (50 x 109/L);\n\n               3. Hemoglobin \u2265 8.0 g/dL (4.96 mmol/L);\n\n               4. Serum AST or ALT within normal limits;\n\n               5. Total bilirubin within normal limits;\n\n               6. Creatinine clearance \u2265 30 mL/min (Cockcroft-Gault calculation);\n\n               7. Serum creatinine \u22641.5 x ULN (correction with hydration and re-testing is\n                  permitted)(values \u2265 1.5 X ULN may be acceptable if improved to < 1.5 x ULN, with\n                  hydration and/or attributable to progressing MM);\n\n               8. Serum calcium (ionized or corrected for albumin) \u2265 2.0 mmol/L (8.0 mg/dL or 1.0\n                  mmol/L ionized calcium) to ULN. Treatment of hypercalcemia or hypocalcemia is\n                  allowed and patient may enroll if serum calcium returns to > 2.0 mmols/L to ULN\n                  with standard treatment\n\n               9. Serum potassium and magnesium within normal limits (correction with\n                  supplementation is permitted);\n\n              10. HgbA1c of \u2264 7%;\n\n              11. Fasting glucose of \u2264126 mg/dL (7.0 mmol/L). A diagnosis of Type II diabetes\n                  mellitus is permitted if > 4 weeks since diagnosis and well controlled.\n                  Concurrent non-insulinotropic antihyperglycemic therapy is permitted if the dose\n                  has been stable for 8 weeks.\n\n         11. Resolution of prior toxicities associated with a prior treatment to\n\n               -  grade 1.\n\n        Exclusion Criteria:\n\n          1. Patients refractory or intolerant to bortezomib are not permitted (Refractory =\n             non-responsive/progressed on therapy or within 60 days of bortezomib) on phase 2 part\n             of the study only.\n\n          2. Diagnosed or treated for another malignancy within 3 years of enrollment, with the\n             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of\n             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.\n\n          3. Patient has received other investigational drugs or chemotherapy within 21 days or\n             approved anti-myeloma therapy including steroid therapy within 14 days prior to first\n             study drug administration.\n\n          4. History (within the last 6 months) of significant cardiovascular disease unless the\n             disease is well-controlled. Significant cardiac disease includes but is not limited\n             to second/third degree heart block; clinically significant ischemic heart disease;\n             superior vena cava (SVC) syndrome; poorly controlled hypertension; congestive heart\n             failure of New York Heart Association (NYHA) Class II or worse. History of arrhythmia\n             (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy,\n             ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or\n             requires treatment (\u2265 grade 3), left bundle branch block (LBBB), or asymptomatic\n             sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation\n             controlled by medication are not excluded;\n\n          5. Mean QTc interval \u2265 450 msec or QTcF interval > 450 msec at screening;\n\n          6. Prior autologous, peripheral stem cell transplant within 12 weeks of the first dose\n             of study drug;\n\n          7. Daily requirement for corticosteroids (except for inhalation corticosteroids);\n\n          8. Patients with evidence of mucosal or internal bleeding and/or platelet transfusion\n             refractory (i.e., unable to maintain a platelet count \u2265 50,000 cells/dL);\n\n          9. Known active infection requiring parenteral or oral anti-infective treatment.\n\n         10. Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or\n             confuse follow-up evaluation.\n\n         11. Use of any medical conditions that, in the Investigator's opinion, would impose\n             excessive risk to the patient. Examples of such conditions include any pre-existing\n             kidney disease (acute or chronic, unless renal insufficiency is felt to be secondary\n             to MM), hypertension, active seizure disorder or pulmonary diseases that would impose\n             excessive risk to the patient.\n\n         12. Patient has hypersensitivity to any of the components of study drugs;\n\n         13. Known HIV or active hepatitis B or C viral infection;\n\n         14. Diabetes mellitus currently requiring insulin or insulinotropic therapy or prior\n             history of steroid induced diabetes ;\n\n         15. History of cerebrovascular accident (CVA) within 6 months prior to registration or\n             that is not stable;\n\n         16. Prior therapy with an IGF-1R inhibitor;\n\n         17. Use of drugs that have a risk of causing QT interval prolongation and/or have a known\n             risk of causing Torsades de Pointes (TdP) before 14 days or the recommended 5\n             half-life washout period elapses (as indicated in Appendix 13-6), which ever is\n             longer prior to Cycle 1 Day 1 dosing;.  Drugs that have a known risk of causing TdP\n             can be found on (www.azcert.org/medical- pros/drug-lists/bycategory.cfm);\n\n         18. Use of strong/moderate CYP1A2 inhibitors such as ciprofloxacin and fluvoxamine. Other\n             less potent CYP1A2 inhibitors/inducers are not excluded (see appendix 13-9)\n\n         19. Gastrointestinal abnormalities, including bowel obstruction, inability to take oral\n             medication, requirement for intravenous (IV) alimentation, active peptic ulcer or\n             prior surgical procedures or bowel resection or other poorly controlled\n             gastrointestinal disorders that could affect the absorption of study drug (eg,\n             Crohn's disease or ulcerative colitis);\n\n         20. Peripheral neuropathy \u2265 grade 2;\n\n         21. Significant liver disease or metastatic disease to the liver;\n\n         22. History of amyloid, plasma cell leukemia or CNS involvement.\n\n         23. Prior radiation therapy or major surgical procedure within 4 weeks of the first dose\n             of study treatment (this does not include limited course of radiation used for\n             management of bone pain)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01672736", 
            "org_study_id": "PMHOSI906-MM001"
        }, 
        "intervention": {
            "arm_group_label": "ASP7487,  Velcade,  Dexamethasone", 
            "description": "ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration", 
            "intervention_name": "ASP7487, Velcade, Dexamethasone", 
            "intervention_type": "Drug", 
            "other_name": [
                "ASP7487", 
                "Bortezomib", 
                "Dexamethasone"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Bortezomib", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Relapsed or relapse/refractory Multiple Myeloma", 
        "lastchanged_date": "December 18, 2013", 
        "location": [
            {
                "contact": {
                    "email": "kbarron@emory.edu", 
                    "last_name": "Kenisha Barron", 
                    "phone": "404-778-5144"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University Winship Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Jonathan Kaufman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kmcdonnell@bsd.uchicago.edu", 
                    "last_name": "Kathryn McDonnell, BS", 
                    "phone": "773-702-1835"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University Of Chicago Medical Center"
                }, 
                "investigator": {
                    "last_name": "Andrzej Jakubowiak, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Donna.mann@cdha.nshealth.ca", 
                    "last_name": "Donna Mann, RN", 
                    "phone": "(902) 429-2597"
                }, 
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3H2Y9"
                    }, 
                    "name": "Queen Elizabeth II Health Sciences Center"
                }, 
                "investigator": {
                    "last_name": "Darrell White, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "engin.gul@uhn.ca", 
                    "last_name": "Engin Gul, HBSc", 
                    "phone": "416 946 4501", 
                    "phone_ext": "2608"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "University Health Network-Princess Margaret Hospital"
                }, 
                "investigator": {
                    "last_name": "Suzanne Trudel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clambert@jgh.mcgill.ca", 
                    "last_name": "Caroline Lambert, PhD", 
                    "phone": "514-340-8222", 
                    "phone_ext": "4599"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3T 1E3"
                    }, 
                    "name": "Sir Mortimer B. Davis-Jewish General Hospital"
                }, 
                "investigator": {
                    "last_name": "Martin Gyger, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nlachapelle.hmr@ssss.gouv.qc.ca", 
                    "last_name": "Nathalie Lachapelle, BSN", 
                    "phone": "514-252-3400", 
                    "phone_ext": "4471"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H1T 2M4"
                    }, 
                    "name": "H\u00f4pital Maisonneuve-Rosemont"
                }, 
                "investigator": {
                    "last_name": "Richard LeBlanc, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1/2 Trial of ASP7487 OSI-906)in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma", 
        "overall_official": {
            "affiliation": "UHN-PMH", 
            "last_name": "Suzanne Trudel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Phase 1: To determine the maximum tolerated dose (MTD) of ASP7487 (OSI-906)  administered in combination with the recommended dose and schedule of bortezomib and dexamethasone;\nPhase 2: To evaluate the antitumor activity of ASP7487 (OSI-906) in combination with bortezomib and dexamethasone at the MTD established from the Phase 1 component.", 
            "measure": "Maximum Tolerated Dose of the combination of ASP7487 (OSI-906) with Velcade and Dexamethasone", 
            "safety_issue": "Yes", 
            "time_frame": "It is estimated that it will take approximately 3-5 months determine MTD.   The efficacy analysis could take upto  2.5 years after the activation date of the study to be completed."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01672736"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Multiple Myeloma Research Consortium", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Astellas Pharma Inc", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}